argenx SE (ARGX), a Dutch immunology company, Friday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has recommended European Commission approval for Subcutaneous Efgartigimod to treat Generalized Myasthenia Gravis or gMG.